Company intelligence / Profile preview

AUPA Biopharm

Hukou, Hsinchu County, Taiwanaupa.com.tw ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

AUPA Biopharm is a Taiwan-based CDMO/CMO with over 30 years of pharmaceutical manufacturing experience. The company provides comprehensive contract drug development and manufacturing services—including formulation design, analytical method development, process optimization, regulatory support, scale-up production, packaging solutions—and specializes in advanced oral solid dosage forms and modified-release technologies. It operates out of a PIC/S GMP-certified facility originally built by Roche in 1991. The company serves both domestic and international pharmaceutical clients.

Therapeutic areas: Other
Modalities: Small molecule (oral solid dosage, modified-release, liquid dosage forms)
Industry: Contract Manufacturing Organization

Partnerships

Collaborates with major domestic and foreign pharmaceutical manufacturers as clients

Beyond the preview

Go deeper on AUPA Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUPA Biopharm.

Explore the full profile